Literature DB >> 8102084

CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells.

D D Schoof1, Y Terashima, G E Peoples, P S Goedegebuure, J V Andrews, J P Richie, T J Eberlein.   

Abstract

The underlying cause for the observed poor antitumor activity of lymphocytes resident, in situ, in freshly resected human renal cell carcinoma (RCC) is unknown. To examine the basis for this observation we evaluated 217 T cell clones established from 20 consecutive patients with renal cell carcinoma. Of these, 75% were CD4+, 22% were CD8+, and 3% were NK+. Cytotoxic T cell function of CD4+ and CD8+ T cell clones was assessed by antibody-induced triggering of the TcR/CD3 complex. Nearly 93% of the CD4+ clones possessed poor cytolytic activity defined as < 50% killing (E:T, 50:1). Alternatively, nearly 80% of CD8+ clones possessed strong cytolytic activity defined as > or = 50% killing. In all T cell clones tested, MHC nonrestricted killing against Daudi or K562 was not observed. Overall, 77% of the T cell clones isolated from patients with RCC in this study were characterized by poor antitumor cytotoxic function; only 22% of the clones displayed strong cytolytic activity. Clones with strong cytotoxic function were tested for cytotoxic function against autologous tumor. However, all clones tested demonstrated little to no tumoricidal activity against autologous tumor. These results indicate that cytolytic T cells, while present in RCC, are not effectively activated by tumor to express CTL function. The immunobiology of CD4+ T cell clones was further evaluated. Thirty-two CD4+ clones from seven patients revealed distinct patterns of cytokine production following TcR/CD3 activation. CD4+ clones could be divided into IL-2 nonproducers and IL-2 producers. A total of 27/32 clones did not produce IL-2 following activation and IFN-gamma production by IL-2 nonproducers was more than threefold less than that by IL-2 producers. However, no differences were found in the levels of IL-4, IL-6, GM-CSF, or TNF-alpha between the two groups. Antitumor cytotoxicity mediated by CD4+ clones did not correlated with cytokine production. These results demonstrate that among T cells resident in human RCC, the predominant type of lymphocyte population consists of noncytolytic helper CD4+ T cells capable of secreting IL-4, but importantly not IL-2, and low levels of IFN-gamma following activation, thus resembling murine Th2 cells. Only a minor contribution by Th0-like cells was observed (i.e., CD4+ clones capable of secreting IL-2, IL-4, and IFN-gamma following activation).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102084     DOI: 10.1006/cimm.1993.1183

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  13 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

3.  Reversal of mucosal tolerance by subcutaneous administration of interleukin-12 at the site of attempted sensitization.

Authors:  A M Claessen; B M von Blomberg; J De Groot; D A Wolvers; G Kraal; R J Scheper
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

Review 4.  Allogeneic stem-cell transplantation in renal-cell carcinoma.

Authors:  B M Hayes-Lattin; R T Maziarz; T M Beer
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

5.  Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU.

Authors:  B Göhring; D Riemann; U Rebmann; H Heynemann; J Schabel; J Langner
Journal:  Urol Res       Date:  1996

6.  In situ cytokine production by breast cancer tumor-infiltrating lymphocytes.

Authors:  B J Camp; S T Dyhrman; V A Memoli; L A Mott; R J Barth
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

Review 7.  The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors.

Authors:  P S Goedegebuure; T J Eberlein
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

8.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

Authors:  N P Restifo; F M Marincola; Y Kawakami; J Taubenberger; J R Yannelli; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1996-01-17       Impact factor: 13.506

9.  Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes.

Authors:  M J Maeurer; D M Martin; C Castelli; E Elder; G Leder; W J Storkus; M T Lotze
Journal:  Cancer Immunol Immunother       Date:  1995-08       Impact factor: 6.968

10.  Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13.

Authors:  D Riemann; A Kehlen; J Langner
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.